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Abstract
Background: Although cigarette smoking is a well-established risk factor for vascular disease, the
genetic mechanisms that link cigarette smoking to an increased incidence of stroke are not well
understood. Genetic variations within the genes of the inflammatory pathways are thought to
partially mediate this risk. Here we evaluate the association of several inflammatory gene single
nucleotide polymorphisms (SNPs) with ischemic stroke risk among young women, further stratified
by current cigarette smoking status.
Methods: A population-based case-control study of stroke among women aged 15–49 identified
224 cases of first ischemic stroke (47.3% African-American) and 211 age-comparable control
subjects (43.1% African-American). Several inflammatory candidate gene SNPs chosen through
literature review were genotyped in the study population and assessed for association with stroke
and interaction with smoking status.
Results: Of the 8 SNPs (across 6 genes) analyzed, only IL6 SNP rs2069832 (allele C, African-
American frequency = 92%, Caucasian frequency = 55%) was found to be significantly associated
with stroke using an additive model, and this was only among African-Americans (age-adjusted: OR
= 2.2, 95% CI = 1.0–5.0, p = 0.049; risk factor adjusted: OR = 2.5, 95% CI = 1.0–6.5, p = 0.05).
When stratified by smoking status, two SNPs demonstrated statistically significant gene-
environment interactions. First, the T allele (frequency = 5%) of IL6 SNP rs2069830 was found to
Published: 26 August 2008
Thrombosis Journal 2008, 6:11 doi:10.1186/1477-9560-6-11
Received: 26 March 2008
Accepted: 26 August 2008
This article is available from: http://www.thrombosisjournal.com/content/6/1/11
© 2008 Cole et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Thrombosis Journal 2008, 6:11 http://www.thrombosisjournal.com/content/6/1/11
Page 2 of 8
(page number not for citation purposes)
be protective among non-smokers (OR = 0.30, 95% CI = 0.11–.082, p = 0.02), but not among
smokers (OR = 1.63, 95% CI = 0.48–5.58, p = 0.43); genotype by smoking interaction (p = 0.036).
Second, the C allele (frequency = 39%) of CD14 SNP rs2569190 was found to increase risk among
smokers (OR = 2.05, 95% CI = 1.09–3.86, p = 0.03), but not among non-smokers (OR = 0.93, 95%
CI = 0.62–1.39, p = 0.72); genotype by smoking interaction (p = 0.039).
Conclusion: This study demonstrates that inflammatory gene SNPs are associated with early-
onset ischemic stroke among African-American women (IL6) and that cigarette smoking may
modulate stroke risk through a gene-environment interaction (IL6 and CD14). Our finding
replicates a prior study showing an interaction with smoking and the C allele of CD14 SNP
rs2569190.
Introduction
Cigarette smoking is a well-established risk factor for vas-
cular disease and stroke. Various mechanisms that link
cigarette smoking to these risks have been described,
including: vasomotor dysfunction [1-3] modification of
the lipid profile (notably increased oxidation of LDL)
[1,2,4], modification of prothrombotic effects, including
altered platelet function [2,5], and deregulation of anti-
thrombotic, prothrombotic, and fibrinolytic mechanisms
[1,2]. The final common pathway shared by these mecha-
nisms is heightened inflammation, which is also consid-
ered a potential risk mechanism [1,2,6]. Each of the
mechanisms is under the influence of multiple genes,
therefore an individuals' susceptibility to the detrimental
effects of cigarette smoke appears to be related to their
pro-inflammatory versus anti-inflammatory gene-specific
allele load. This hypothesis is supported by multiple stud-
ies that indicate pro-inflammatory gene-specific allele
load is associated with enhanced inflammation and early
atherosclerosis in smokers [7-10]. Many inflammatory
genes have been implicated in these relationships, specific
to this study these include: interleukin-1A (IL1A; OMIM
147760), interleukin-1 receptor – type I precursor (IL1R1;
OMIM 147810), interleukin-1B (IL1B; OMIM 147720),
interleukin-6 (IL6;  OMIM 147620), stromelysin-1
(MMP3; OMIM 185250), and monocyte endotoxin recep-
tor (CD14; OMIM 158120). In this study, we analyze the
relationships between various polymorphisms of these
genes, ischemic stroke risk, and smoking status.
Research design and methods
Study subjects
The Stroke Prevention in Young Women Study 2 (SPYW2)
is a population-based case-control study that was
designed to examine genetic risk factors for ischemic
stroke in young women. The term "population-based"
indicates that the cases and the comparison control group
were identified from the same population including all of
Maryland (except the far Western panhandle), Washing-
ton DC, and the southern portions of both Pennsylvania
and Delaware. Two hundred thirty nine female cases age
15 to 49 years of age with a first cerebral infarction were
identified by discharge surveillance at 51 regional hospi-
tals and through direct referral by regional neurologists.
The methods for discharge surveillance, chart abstraction,
and case adjudication have been described previously [11-
13]. We determined each subject's case-control status (i.e.
determined subjects who had a stroke) blinded to genetic
information. Strokes were classified as having a probable,
possible or undetermined etiology [11,12]. Using prede-
termined exclusion criteria, modified from the Siblings
With Ischemic Stroke Study (SWISS) protocol [14], we
excluded 15 cases with the following characteristics: sickle
cell disease (n = 1), CNS vasculitis by angiogram and clin-
ical criteria (n = 3), post-radiation arteriopathy (n = 1),
endocarditis (n = 3), neurosyphillis (n = 1), mechanical
prosthetic heart valves (n = 2), left atrial myxoma (n = 1),
and cocaine use in the 48 hours prior to their stroke (n =
3). Controls subjects (212 women without a history of
stroke), were identified by random digit dialing and were
frequency matched to the cases by age and geographic
region of residence. One control was excluded from anal-
yses based on a history of sickle cell disease. Thus, the
sample for genetic analyses consisted of 224 cases and 211
controls.
Cases and controls were grouped into the following race-
ethnic categories: Caucasian (non-Hispanic) (95 cases
and 99 controls), African-American (105 cases and 91
controls), and other (including Hispanic, Asian, Ameri-
can-Indian, etc.) (24 cases and 21 controls). Because of
the small size and heterogeneity of the latter group, it was
not analyzed separately, but was included within the com-
bined total study group (224 cases and 211 controls).
Strokes were further classified by subtype: the atheroscle-
rotic group included 27 cases with either probable or pos-
sible atherosclerotic mechanism, the cardiac group
included 14 cases with a probable cardiac source of embo-
lism, the probable dissection group included 13 cases
confirmed by neuroimaging, the lacunar group included
45 cases of symptomatic small deep lesions on neuroim-
aging studies or classic lacunar syndromes regardless of
other potential causes, and the probable hematologic
group included 9 cases. These categories were not mutu-Thrombosis Journal 2008, 6:11 http://www.thrombosisjournal.com/content/6/1/11
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ally exclusive. There were 125 non-lacunar stroke cases of
undetermined etiology.
Single Nucleotide Polymorphisms (SNPs) evaluated
We identified genes and SNPs that influence inflamma-
tion through a literature review seeking an association of
the genes and SNPs with vascular disease (stroke, myocar-
dial infarction, peripheral vascular disease, or atheroscle-
rosis). If the evidence suggested that smoking might
modify the relationship between gene or SNP and stroke
through a gene-environment interaction, a higher priority
for inclusion in our analyses was assigned to that gene or
SNP. Because we sought to evaluate common SNPs, only
those SNPs with a minor allele frequency of 0.05 or
greater among African-Americans or Caucasians as per the
NCBI SNP website http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?CMD=search&DB=snp were evaluated. After
weighing these considerations, the final list of genes and
SNPs analyzed in this study included: CD14 (rs2569190),
IL1A (rs17561), IL1R1 (rs3917318), IL1B (rs3917365),
IL6  (rs1800797, rs2069830, 2069832), and MMP3
(rs679620).
Genotyping methods for the case/control population
Genotyping was conducted on DNA isolated from whole
blood using the QIAamp DNA Blood Maxi Kit (Qiagen,
Valencia, CA). SNP genotyping was performed by one of
two methods. The first method, developed for a SNP
stream Ultra-High Throughput machine (Beckman Coul-
ter, Inc., Fullerton, CA) is capable of genotyping up to 12-
SNPs simultaneously. Sequences surrounding the SNPs
were obtained from GenBank http://
www.ncbi.nlm.nih.gov/Genbank/index.html and sub-
mitted to Autoprimer.com (Beckman Coulter, Inc.). For
each SNP, three primers were designed, two for PCR
amplification and an internal primer with a 5' DNA
sequence tag. Pairs of primers were used to initiate PCR
amplification. The free primers were removed by enzy-
matic digestion using Exonuclease I and Shrimp Alkaline
Phosphotase (Beckman Coulter, Inc.). The internal prim-
ers were used to initiate a sequencing reaction that adds
one labeled base for the alternative nucleotides of each
SNP to have distinct labels. The labeled products are sep-
arated on a SNP-IT plate consisting of 384 mini-arrays
with 16-spots each (Beckman Coulter, Inc.). For each
individual DNA sample, 16 spots hybridized to the two
homozygotes, the heterozygote, a negative control and
the 12-labeled primers associated with the 12-SNPs. Thus,
every PCR and labeling reaction had internal controls to
confirm the success of the reactions and the appropriate-
ness of the fluorescent outputs for each DNA sample.
SNPs genotyped using this method include: IL1R1
(rs3917318);  IL1B  (rs3917365);  IL6  (rs1800797,
2069832).
The second genotyping method was Taqman (Applied
Biosystems). This method is based on four primers, two
flanking the SNP that are used to amplify the DNA sur-
rounding the SNP and two, one for each alternative allele,
that were labeled with different fluorescent dyes. The orig-
inal form of the labeled primer has a quencher in close
proximity to the dye. However, when the exonuclease
activity of DNA polymerase disrupts the primer hybrid-
ized to the single strand DNA during the PCR, then
quencher and the dye are released and the fluorescence
can be measured. The reaction itself follows manufac-
turer's instructions included with each individual primer
set. SNPs genotyped using this method include: CD14
(rs2569190);  IL1A  (rs17561);  IL6  (rs2069830);  MMP3
(rs679620).
Analyses
All statistical analyses were performed using SAS®, Version
9.1 (SAS Institute, Cary, NC). We compared means by
two-sided t-tests and proportions by χ2 tests. All SNPs
were verified to be in Hardy-Weinberg equilibrium.
Adjusted odds ratios from logistic regression were used to
determine whether the presence of the risk allele was asso-
ciated with an increased risk for ischemic stroke after con-
trolling for potential confounders.
Two additive models were used to determine the relation
between SNP and outcome. The first model (our primary
analyses) was adjusted for age and race (when all subjects
were included in the analysis) or only age when the anal-
ysis was stratified by race (i.e. African-Americans and Cau-
casians). The second model, (adjusted model) added
history of hypertension, diabetes, smoking, oral contra-
ceptive (OCP) use and angina pectoris or myocardial inf-
arction (angina-MI), to age (or age and race) to the
independent variables used in the first model. The results
of the analyses were expressed as odds ratios which quan-
tify the increased risk of ischemic stroke associated with
each additional risk allele. Age, race, current cigarette
smoking status, and OCP use were determined by subject
reports (or proxy report, if a participant was unable to
answer). Hypertension and diabetes mellitus were deter-
mined by asking study participants (or a proxy) if a physi-
cian had ever told them they had the condition. Current
smoking was defined as having one or more cigarettes in
the month (31 days) preceding their stroke, or for con-
trols, in the month prior to their interview. Current oral
contraceptive use was also defined as use in the prior
month.
In order to evaluate each SNP for a genotype by smoking
interaction (as per our initial hypothesis), study partici-
pants were stratified by smoking status and evaluated in
an age-, race-adjusted additive model. For those SNPs that
demonstrated a potential genotype by smoking interac-Thrombosis Journal 2008, 6:11 http://www.thrombosisjournal.com/content/6/1/11
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tion the significance of the difference between the point
estimates (i.e. the log odds ratios) in smokers and non-
smokers was tested using a z-test. Lastly, SNPs with signif-
icant z-test results were additionally evaluated for poten-
tial race-specific smoking interactions in an age-adjusted
additive model, with the SNP stratified by smoking status
further stratified by race (Caucasian and African-Ameri-
can).
In secondary analyses, significantly associated SNPs from
the primary analyses (total population and race-stratified)
underwent further analyses to evaluate groups stratified
by other standard risk factors (age, hypertension, diabetes
mellitus, OCP use, and history of angina/MI) and
ischemic stroke subtype (atherosclerotic, cardiac, dissec-
tion, lacunar, hematologic, and stroke of unknown etiol-
ogy (i.e. all other stroke)) with the later groups compared
to all controls. Additionally, analyses consisting of domi-
nant and recessive genetic models that included similar
groups and covariates to the primary analyses were also
performed. We did not adjust for multiple comparisons




Demographic and risk factor characteristics by case-con-
trol status are described in Table 1. The mean age of the
cases was 41.7 years and the mean age of control subjects
was 39.6 years. Cases were significantly more likely than
controls to have a history of hypertension (p < 0.0001),
diabetes (p = 0.0002), angina-MI (p = 0.0005), to cur-
rently smoke cigarettes (p < 0.0001), and to report the use
of oral contraceptive pills (OCP) within the month prior
to their stroke (p = 0.032).
Ischemic stroke risk
Table 2 gives p-values for the age-adjusted additive model
and risk factor-adjusted additive model for the eight SNPs
stratified by race and case-control status, and also pro-
vides each SNPs location, allelic variants, and genotype
call rate. Of the SNPs analyzed, only the IL6  SNP
rs2069832 (C allele; overall frequency: African-Americans
= 92%, Caucasians = 55%) was found to be significantly
associated with stroke, and this was only among African-
Americans (Age-adjusted model: OR = 2.2, 95% CI =
1.0–5.0, p = 0.049; Risk Factor model: OR = 2.5, 95% CI
= 1.0–6.5, p = 0.05). Dominant and recessive models did
not strengthen the association (data not shown). Stratify-
ing participants by other risk factors and evaluating stroke
risk in relation to SNP rs2069832 genotype revealed no
associations with stroke (data not shown). Stratifying par-
ticipants by stroke subtype as compared to all controls
and evaluating stroke risk in relation to SNP rs2069832
genotype revealed no significant associations (data not
shown).
Ischemic stroke risk as stratified by smoking status
Table 3 demonstrates the age- and race-adjusted additive
model results for the SNPs stratified by smoking status.
Two SNPs demonstrated a gene-environment interaction
based upon smoking status. First, CD-14 SNP rs2569190
(C allele; frequency in total population = 39%) was found
to be associated with increased risk of stroke among
smokers (OR = 2.05, 95% CI = 1.09–3.87, p = 0.027), but
not non-smokers (OR = 0.93, 95% CI = 0.62–1.39, p =
0.72). The two odds ratios were significantly different (p
= 0.039). Secondly, IL6  SNP rs2069830 (T allele; fre-
quency in total population = 5%) was found to be protec-
tive among non-smokers (OR = 0.30, 95% CI =
0.11–.082, p = 0.02), but not among smokers (OR = 1.63,
95% CI = 0.48–5.58, p = 0.43). The two odds ratios were
significantly different (p = 0.036).
Ischemic stroke risk as stratified by smoking status further 
stratified by race
Results of the race-stratified smoking-genotype interac-
tion analyses demonstrated no significant interactions.
However, the race-stratified point estimates (ORs)
remained similar to the combined population point esti-
mates as detailed in the preceding paragraph. For CD-14
SNP rs2569190, similar ORs were seen among both
smokers of both races (Caucasian OR = 2.21, p = 0.127;
African-American OR = 1.91, p = 0.143) and non-smokers
of both races (Caucasian OR = 1.18, p = 0.60; African-
American OR = 0.83, p = 0.55). For IL-6 SNP rs2069830,
Table 1: Characteristics, by case-control status.
Cases (N = 224) Controls (N = 211) p-value
Mean age (years) 41.7 39.6 0.0026
African-American (%) 47.3 43.1 0.579
Hypertension (%) 41.1 14.2 <.0001
Diabetes mellitus (%) 17.9 6.2 0.0002
Current smokers (%) 47.8 23.7 <.0001
Angina-MI (%) 11.6 2.8 0.0005
OCP (%)* 12.2 6.2 0.032






























































































































Table 2: Proinflammatory SNPs stratified by race and case/control status demonstrating allelic variants, genotype call rate, minor allele frequencies and p-values for age-adjusted additive 
model and risk factor adjusted additive model.
Gene SNP rs number, location and 
function
Alleles* Call Rate (%) African-Americans Caucasians













Age-adjusted Risk factor 
adjusted**
CD14ψ rs2569190, 5' promotor C/T 99% 0.38/77 0.42/62 0.57 0.66 0.49/65 0.40/75 0.13 0.30
IL1A rs17561, exon 4 nonsynonymous G/T 98% 0.18/102 0.18/90 0.83 0.73 0.27/93 0.31/94 0.32 0.80
IL1R1 rs3917318, intron 10 A/G 91% 0.33/97 0.29/88 0.44 0.23 0.33/92 0.36/92 0.53 0.24
ILIB rs3917365, 3' near gene C/T 81% 0.21/97 0.17/83 0.34 0.36 0.08/86 0.08/89 0.85 0.87
IL6 rs1800797, 5' near gene A/G 91% 0.06/99 0.10/88 0.19 0.18 0.42/93 0.43/91 0.89 0.87
rs2069830, exon 2 nonsynonymous C/T 91% 0.07/100 0.09/87 0.32 0.31 0.01/90 0.03/93 0.30 0.35
rs2069832, intron 2 C/T 89% 0.05/97 0.12/86 0.049 0.05 0.45/92 0.45/91 0.97 0.85
MMP3 rs679620, exon 2 nonsynonymous C/T 89% 0.35/103 0.35/88 0.95 0.72 0.45/90 0.47/96 0.85 1.0
ψCD14 SNP rs2569190 was genotyped in a smaller case-control sample (N = 315).
* Minor allele in African-Americans (bolded in column 3 above).
** Risk factor adjusted – Additive model adjusted for age, hypertension, diabetes, oral contraceptive use, and angina-MI.
Table 3: Proinflammatory SNPs stratified by smoking status demonstrating the number of cases and controls, and Odds Ratio, 95%CI and p-values in an age-, race-adjusted additive 
model.
Gene rs number Smokers Non-Smokers
Cases/Controls OR* 95% CI p-value Cases/Controls OR* 95% CI p-value
CD14 rs2569190 77/31 2.05 1.09–3.87 0.027 82/121 0.93 0.62–1.39 0.72
IL1A rs17561 106/48 1.68 0.84–3.32 0.14 111/156 1.05 0.69–1.60 0.83
IL1R1 rs3917318 102/45 1.138 0.67–1.94 0.64 108/155 1.07 0.74–1.54 0.72
IL1B rs3917365 99/44 1.63 0.78–3.42 0.19 105/146 1.03 0.62–1.73 0.90
IL6 rs1800797 104/43 1.28 0.66–2.46 0.46 110/155 1.05 0.67–1.64 0.83
rs2069830 103/45 1.63 0.48–5.58 0.43 109/155 0.30 0.11–0.82 0.019
rs2069832 101/45 0.69 0.35–1.35 0.28 109/152 0.80 0.51–1.26 0.34
MMP3 rs679620 103/46 0.98 0.58–1.65 0.93 110/157 1.01 0.71–1.43 0.97
* Adjusted for age and race (African-American, Caucasian, and other).Thrombosis Journal 2008, 6:11 http://www.thrombosisjournal.com/content/6/1/11
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among African-Americans, similar ORs as found in the
combined population were seen among smokers (OR =
1.31, p = 0.71) and non-smokers (OR = 0.38, p = 0.10),
consistent with a protective effect for the T allele among
non-smokers. For IL-6 SNP rs2069830, among both Cau-
casian non-smokers and smokers, the logistic regression
models did not converge due to the low frequency (2%)
of the T allele.
Discussion
Our study did not demonstrate strong relationships
between the inflammatory gene polymorphisms and
ischemic stroke risk. Only IL6 (rs2069832) was found to
be associated with stroke, and only among African-Amer-
icans. However, it did identify two polymorphisms that
appear to influence stroke risk via a gene-environment
interaction with cigarette smoking, IL6 rs2069830 and
CD-14 rs2569190.
IL-6 plays a key role in the acute inflammatory response
and in regulation of the production of acute phase pro-
teins such as C-reactive protein [15,16]. It contributes to
the inflammatory response by activating endothelial cells
[15,17] and stimulating the synthesis of fibrinogen
[15,18]. In vivo exposure to cigarette smoke has been
shown to increase the expression of proinflammatory
cytokines including IL-6 [19]. Furthermore, several stud-
ies have demonstrated that IL-6 polymorphisms may
mediate carotid artery intima-media wall thickness
[20,21], an intermediate marker of stroke risk. Our results,
consistent with other studies, demonstrates that genetic
variation in IL-6 may modify stroke risk [15,22], and that
this increased risk may be due to synergistic effects
between proinflammatory genotypes and smoking [23].
CD14 is a surface protein preferentially expressed on
monocytes and macrophages that acts to bind lipopoly-
saccharide-binding protein (also called endotoxin). Endo-
toxin is a potent mediator of inflammation, and smokers
have elevated plasma levels of endotoxin. Hence, it is
believed that the risk of atherosclerosis from endotoxemia
is increased in smokers [24]. The CD14 SNP rs2569190 is
a C > T substitution in the proximal CD14 promoter GC
box at position -260 from the translation start site and
results in a HaeIII restriction site [25]. The results of stud-
ies which have tried to determine which allele mediates
vascular risk have been variable. The T allele was associ-
ated with an increased risk of MI [25-28] and two
ischemic stroke subtypes including atherosclerosis of
large arteries and microangiopathy [29]. Contrary to these
studies, the C allele was associated with a higher risk of
carotid plaque formation [30], and was found to act syn-
ergistically with other inflammatory SNPs to increase
carotid IMT [7,9], specifically among smokers [7]. Still
other studies evaluating this SNP have found no associa-
tion with stroke [31,32]. Our results support a gene-envi-
ronment association between the C allele and ischemic
stroke risk among smokers. Our findings replicate a prior
study showing an interaction with smoking and the C
allele of CD14 SNP rs2569190 [7].
Our study has several limitations. Most notably, we only
evaluated a limited number of SNPs, which were not suf-
ficient to comprehensively evaluate stroke risk or smoking
interaction for any of the genes studied. Secondly, our
study did not provide any mechanistic information
regarding stroke risk or protection. Specifically, we did not
determine if our SNPs were associated with increased or
decreased protein activity. Furthermore, our study popu-
lation is relatively small and is underpowered to detect
modest effects, particularly in the stroke subtype analyses.
Although we have attempted to minimize phenotypic het-
erogeneity through identifying ischemic stroke subtypes
during adjudication, we recognize that residual pheno-
typic heterogeneity may exist. Lastly, though we per-
formed numerous analyses, no correction was made for
multiple comparisons. This allows for the possibility that
our results could be attained through chance alone,
although confirming CD-14 rs2569190 as a mediator of
vascular risk, and specifically among smokers of both
races, makes such a false positive association less likely.
Conclusion
This study demonstrates that inflammatory gene SNPs
may be associated with early-onset ischemic stroke among
African-American women (IL6) and that cigarette smok-
ing may modulate stroke risk through a gene-environ-
ment interaction (IL6 and CD14).
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